Why This Shrinking Covid-19 Vaccine Stock Jumped 30%
In This Article:
Vaccine maker Novavax stock jumped double digits on Thursday after the company reported its quarterly sales had more than fivefold. Novavax also said it is in discussions with the Food and Drug Administration about full approval for its Covid-19 vaccine, Nuvaxovid, which has only the emergency approval it received in the pandemic. The FDA delayed full approval in April.
Terms and Privacy Policy